The scientific distinction of Tirzepatide lies in its dual receptor engagement mechanism. GIP receptor agonism stimulates insulin secretion, promotes adipogenesis regulation, and influences bone metabolism and cognitive function through pathways entirely separate from the GLP-1 axis. GLP-1 receptor agonism contributes complementary insulin secretion stimulation, glucagon suppression, gastric motility modulation, and hypothalamic appetite signaling. The simultaneous activation of both pathways through a single molecule creates a synergistic incretin effect that researchers are actively investigating for its implications in metabolic disease biology, obesity mechanisms, and cardiovascular risk factor modulation.

GLP-2 TZ provides access to this dual-receptor research paradigm in a standardized, research-grade formulation enabling investigators to study the integrated metabolic consequences of combined GIP and GLP-1 receptor co-activation, compare the dual-agonist profile against selective single-receptor reference compounds, and investigate the relative contributions of each receptor pathway to observed metabolic outcomes through selective antagonist studies.

Research applications include dual GIP/GLP-1 receptor co-agonism and synergistic incretin effect studies, comparative pharmacology research against selective GLP-1 and GIP mono-agonists, pancreatic beta and alpha cell function under dual incretin stimulation, adipose tissue biology and lipid metabolism regulation research, hypothalamic energy homeostasis and appetite regulation investigations, cardiovascular risk marker modulation studies, and receptor pathway contribution analysis using selective antagonist experimental designs.

All GLP-2 TZ vials are independently HPLC-validated and mass-spectrometry confirmed, with complete third-party COA documentation available.

Active Compound: Tirzepatide
Storage: Lyophilized at −20°C | Reconstitute under sterile conditions
For Research Use Only